RS60432B1 - Upotreba glp-1 peptida sa dugim dejstvom - Google Patents

Upotreba glp-1 peptida sa dugim dejstvom

Info

Publication number
RS60432B1
RS60432B1 RS20200684A RSP20200684A RS60432B1 RS 60432 B1 RS60432 B1 RS 60432B1 RS 20200684 A RS20200684 A RS 20200684A RS P20200684 A RSP20200684 A RS P20200684A RS 60432 B1 RS60432 B1 RS 60432B1
Authority
RS
Serbia
Prior art keywords
peptides
long
acting glp
glp
acting
Prior art date
Application number
RS20200684A
Other languages
English (en)
Inventor
Christine Bjørn Jensen
Mads Frederik Rasmussen
Milan Zdravkovic
Peter Kristensen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49881374&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS60432(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of RS60432B1 publication Critical patent/RS60432B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RS20200684A 2012-07-01 2013-06-21 Upotreba glp-1 peptida sa dugim dejstvom RS60432B1 (sr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP12174535 2012-07-01
US201261694837P 2012-08-30 2012-08-30
US201261708162P 2012-10-01 2012-10-01
EP12186781 2012-10-01
PCT/EP2013/063004 WO2014005858A1 (en) 2012-07-01 2013-06-21 Use of long-acting glp-1 peptides
EP13737808.9A EP2866825B1 (en) 2012-07-01 2013-06-21 Use of long-acting glp-1 peptides

Publications (1)

Publication Number Publication Date
RS60432B1 true RS60432B1 (sr) 2020-07-31

Family

ID=49881374

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20200684A RS60432B1 (sr) 2012-07-01 2013-06-21 Upotreba glp-1 peptida sa dugim dejstvom

Country Status (11)

Country Link
US (2) US9764003B2 (sr)
EP (3) EP3689365A1 (sr)
JP (1) JP6059802B2 (sr)
AU (3) AU2013286177B2 (sr)
BR (1) BR112014032938A2 (sr)
CA (1) CA2877056A1 (sr)
MX (2) MX366405B (sr)
RS (1) RS60432B1 (sr)
RU (1) RU2657573C2 (sr)
SI (1) SI2866825T1 (sr)
WO (1) WO2014005858A1 (sr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2651398T3 (en) 2010-12-16 2018-03-12 Novo Nordisk As Solid compositions comprising a GLP-1 agonist and a salt of N- (8- (2-hydroxybenzyl) amino) caprylic acid
KR101972836B1 (ko) 2011-04-12 2019-04-29 노보 노르디스크 에이/에스 이중 아실화된 ｇｌｐ-1 유도체
RS57727B1 (sr) 2012-03-22 2018-12-31 Novo Nordisk As Kompozicije glp-1 peptida i njihovo dobijanje
CN104487056A (zh) 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） 包含肽和递送剂的片剂制剂
EP3689365A1 (en) 2012-07-01 2020-08-05 Novo Nordisk A/S Use of long-acting glp-1 peptides
EP3208131B1 (en) * 2014-10-16 2020-12-02 Yanmar Power Technology Co., Ltd. Work vehicle
GB201621987D0 (en) * 2016-12-22 2017-02-08 Archer Virgil L See Archer Sheri A Arecor Ltd Novel composition
DE102017106216A1 (de) * 2017-03-22 2018-09-27 Amw Gmbh Extrudierte Depotform zur anhaltenden Wirkstofffreisetzung
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
BR112020006246A2 (pt) * 2017-10-12 2021-03-30 Novo Nordisk A/S Método para controle do peso de um sujeito em necessidade
GB201720187D0 (en) * 2017-12-04 2018-01-17 Imperial Innovations Ltd Novel Compounds
WO2019149880A1 (en) 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
US20210162013A1 (en) * 2018-08-03 2021-06-03 Brown University Compositions and methods for improving the bioavailability of glp1 and analogues thereof
IL291876A (en) * 2019-11-06 2022-06-01 Novo Nordisk As Receptor agonists in glp-1 type dementia
IL294521A (en) * 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses
CN112768087A (zh) * 2020-12-23 2021-05-07 吉林大学 利用孟德尔随机化方法验证索马鲁肽口服制剂预防二型糖尿病的用途
JP2024527528A (ja) * 2021-06-24 2024-07-25 ギラ セラピューティクス インコーポレイテッド 満腹感を誘導する、及び代謝障害を治療するための方法及びキット
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
CN114621339B (zh) * 2021-12-28 2022-09-23 北京惠之衡生物科技有限公司 一种长效glp-1衍生物
US20230374096A1 (en) * 2022-05-19 2023-11-23 Vault Bioventures, Inc. Obesity treatment and prevention methods
WO2024141760A1 (en) 2022-12-30 2024-07-04 Algipharma As Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
EP1826216A1 (en) 1996-08-30 2007-08-29 Novo Nordisk A/S Glp-1 derivatives
EP1412384B1 (en) 2001-06-28 2007-12-26 Novo Nordisk A/S Stable formulation of modified glp-1
BR122019021416A2 (sr) 2003-09-19 2019-12-21
CN113304250A (zh) 2003-11-20 2021-08-27 诺和诺德股份有限公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
KR101340354B1 (ko) * 2004-11-12 2013-12-11 노보 노르디스크 에이/에스 안정한 펩티드 제제
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
RU2409349C2 (ru) * 2006-04-14 2011-01-20 Маннкайнд Корпорейшн Фармацевтические композиции, содержащие глюкагонподобный пептид(glp-1)
EP2121897A4 (en) 2007-03-20 2010-03-31 Nippon Kayaku Kk METHOD FOR MONITORING THE DRUG EFFECT ON DIABETES PATIENTS USING AN ASSAY FOR 1,5-ANHYDRO-D-GLUCITOL
EP2164466A1 (en) 2007-06-01 2010-03-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
US8895694B2 (en) 2007-09-05 2014-11-25 Novo Nordisk A/S Glucagon-Like Peptide-1 derivatives and their pharmaceutical use
CN101842386A (zh) 2007-09-05 2010-09-22 诺沃-诺迪斯克有限公司 截短的glp-1衍生物和它们的治疗用途
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
ES2620610T3 (es) 2008-12-10 2017-06-29 Glaxosmithkline Llc Composiciones farmacéuticas de albiglutide
CN106177958A (zh) * 2009-02-13 2016-12-07 勃林格殷格翰国际有限公司 包含dpp‑4抑制剂(利拉列汀)任选地组合其它抗糖尿病药的抗糖尿病药物
CN104311657B (zh) * 2009-12-16 2020-12-08 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
WO2011138421A1 (en) * 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
DK2651398T3 (en) 2010-12-16 2018-03-12 Novo Nordisk As Solid compositions comprising a GLP-1 agonist and a salt of N- (8- (2-hydroxybenzyl) amino) caprylic acid
US20130035281A1 (en) * 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102718858B (zh) 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
CN102229668A (zh) 2011-06-03 2011-11-02 浙江贝达药业有限公司 一种glp-1衍生物及其应用
CN103906528A (zh) 2011-06-24 2014-07-02 安米林药品有限责任公司 用glp-1受体激动剂的缓释制剂治疗糖尿病的方法
EP3689365A1 (en) 2012-07-01 2020-08-05 Novo Nordisk A/S Use of long-acting glp-1 peptides

Also Published As

Publication number Publication date
AU2013286177B2 (en) 2018-04-26
AU2018202504B2 (en) 2020-05-07
US20180085435A1 (en) 2018-03-29
US9764003B2 (en) 2017-09-19
EP4406593A3 (en) 2024-10-23
EP4406593A2 (en) 2024-07-31
RU2015101826A (ru) 2016-08-20
AU2020202573A1 (en) 2020-05-07
JP6059802B2 (ja) 2017-01-11
CA2877056A1 (en) 2014-01-09
US20150190474A1 (en) 2015-07-09
RU2657573C2 (ru) 2018-06-14
MX366405B (es) 2019-07-08
AU2020202573B2 (en) 2023-04-20
EP2866825A1 (en) 2015-05-06
MX2020010693A (es) 2020-11-06
EP3689365A1 (en) 2020-08-05
EP2866825B1 (en) 2020-04-08
MX2014014946A (es) 2015-04-08
SI2866825T1 (sl) 2020-07-31
US10335462B2 (en) 2019-07-02
AU2018202504A1 (en) 2018-05-10
AU2013286177A1 (en) 2015-01-15
JP2015522573A (ja) 2015-08-06
WO2014005858A1 (en) 2014-01-09
BR112014032938A2 (pt) 2017-08-01

Similar Documents

Publication Publication Date Title
SI2866825T1 (sl) Uporaba dolgo delujočih peptidov GLP-1
HRP20181447T1 (hr) Pripravci glp-1 peptida i njihova priprava
SG11201400432VA (en) Polypeptide vaccine
TWI561242B (en) Long-acting peptide analogs
EP2857033A4 (en) SKIN-PUNKING PEPTIDE
ZA201406082B (en) Use of ccr3-inhibitors
IL238651A0 (en) Long-acting, single-chain insulin analogs
EP2914293A4 (en) METHOD OF USE OF FVIII POLYPEPTIDE
EP2812347A4 (en) AUTOPHAGIA-INDUCING PEPTIDE
HK1209138A1 (en) Peptides
GB201200555D0 (en) Peptide
GB201204868D0 (en) Peptides
GB201223114D0 (en) Novel peptide
PT2866825T (pt) Uso de péptidos glp-1 de longa ação
EP2891663A4 (en) PEPTIDE DERIVED FROM PSF1
GB201217908D0 (en) Retractable footrest
PT3824876T (pt) Formulações de longa ação de insulinas
IL234228B (en) Compositions of glp-1 peptides and preparation thereof
GB201221414D0 (en) Trans-locating peptide
GB201220328D0 (en) Peptides
GB201211740D0 (en) Peptides
GB201207895D0 (en) Peptides
TWM433525U (en) Structure of calorifier
GB201200624D0 (en) Peptide
GB201200623D0 (en) Peptide